ArticleBMC cardiovascular disorders2026
Triglyceride glucose index, metabolic comorbidity, and cardiovascular disease: a national cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe triglyceride-glucose (TyG) index, a widely accepted surrogate biomarker of insulin resistance, strongly predicts cardiovascular disease (CVD) risk. However, the mediating role of metabolic comorbidities in explaining the relationship between the TyG index and cardiovascular disease remains underexplored. Leveraging the longitudinal data from the China Health and Retirement Longitudinal Study (CHARLS), this longitudinal study investigates how metabolic comorbidities mediate the association between the TyG index and cardiovascular risk.
methodsThis analysis included 9,400 participants aged ≥ 45 years from CHARLS without baseline CVD. The TyG index was computed as Ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]. Incident cardiovascular events, which were defined as physician-confirmed heart disease or stroke, were monitored until 2020. Adjusted Cox proportional hazards models estimated hazard ratios (HR). The mediation analysis quantified the percentage of excess risk (PERM) attributable to metabolic comorbidities.
resultsThe mean age of the participants was 59.0 ± 9.5 years, and 4 862 (51.7%) were females. Among eligible participants, 2,152 developed cardiovascular diseases over a 9-year follow-up, with 1,627 heart disease cases and 765 strokes. Compared with people with a lower TyG index (< 8.59 [median level]) and no comorbidity, those concurrently with a higher TyG and comorbidity had the highest risk of CVD (adjusted HR, 1.66; 95% CI, 1.47-1.88), coronary heart disease (aHR, 1.44; 95% CI, 1.25-1.66) and stroke (aHR, 2.94; 95% CI, 2.31-3.75). Metabolic comorbidities mediated 48.3% of the TyG-associated CVD risk, predominantly through hypertension, renal impairment, inflammation, and obesity.
conclusionThese findings underscore the partial mediating role of metabolic comorbidities in the TyG index-CVD association. Future research should explore residual pathways to fully elucidate this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.